Systemic therapies for hepatocellular carcinoma: an evolving landscape

Abstract

In the last few years, there has been a significant widening of the landscape of systemic therapy for unresectable hepatocellular carcinoma (HCC) patients. After the landmark drug sorafenib, several other molecules have been approved for treatment in first-line (lenvatinib) and second-line (regorafenib, cabozantinib, and ramucirumab) regimens. Very recently, another important step forward has been made with the demonstration that the combination of an anti-programmed death ligand 1 and an anti-vascular endothelial growth factor (atezolizumab + bevacizumab) provides better survival results compared to sorafenib, thus becoming the new paradigm in first-line treatment of HCC. In consideration of this rapidly evolving situation, with the availability of many potential active drugs, the American Society of Clinical Oncology recently published a guideline in order to advise on the selection of systemic treatment options. However, also considering the uncertainties and the unmet needs in the current treatment of patients with advanced liver cancer is mandatory.

Keywords

Hepatocellular carcinoma, systemic therapies, tyrosine kinase inhibitors, immune checkpoint inhibitors, atezolizumab, bevacizumab / American Society of Clinical Oncology (ASCO)

References

[1] Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2012;56:908-43

[2] Ramadori G,Grabbe E,Armbrust T.Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis.Anticancer Drugs2004;15:405-9

[3] Llovet JM,Mazzaferro V.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[4] Cheng AL,Chen Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009;10:25-34

[5] Villanueva A.Hepatocellular carcinoma.N Engl J Med2019;380:1450-62

[6] Bruix J,Merle P.RESORCE InvestigatorsRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;389:56-66

[7] Abou-Alfa GK,Cheng A-L.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.N Engl J Med2018;379:54-63 PMCID:PMC7523244

[8] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[9] Zhu AX,Yen CJ.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations ( REACH-2 ): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019;20:282-96

[10] Finn RS,Ikeda M.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[11] Gordan JD,Abou-Alfa GK.Systemic therapy for advanced hepatocellula carcinoma: ASCO Guideline.J Clin Oncol2020;38:4317-45

[12] Yau T,Finn RS.LBA38_PR - CheckMate 459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).Ann Oncol2019;30 (suppl_5):v874-5

[13] Finn RS,Merle P.KEYNOTE-240 investigatorsPembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial.J Clin Oncol2020;38:193-202

[14] Siegel AB,Ocean A.Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.J Clin Oncol2008;26:2992-8 PMCID:PMC3635806

[15] Boige V,Bourredjem A.Efficacy, safety, and biomarkers of single - agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.Oncologist2012;17:1063-72 PMCID:PMC3425524

[16] Finn RS.Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.Expert Rev Anticancer Ther2009;9:503-9

[17] Zhu AX,Sahani DV.HCC and angiogenesis: possible targets and future directions.Nat Rev Clin Oncol2011;8:292-301 PMCID:PMC3266719

[18] Kudo M.Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and vegf inhibitors in advanced hepatocellular carcinoma.Cancers (Basel)2020;12:1089 PMCID:PMC7281246

[19] Fukumura D,Amoozgar Z,Jain RK.Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges.Nat Rev Clin Oncol2018;15:325-40 PMCID:PMC5921900

[20] Chouaib S,Couve S,Hasmim M.Hypoxia promotes tumor growth in linking angiogenesis to immune escape.Front Immunol2012;3:21 PMCID:PMC3341970

[21] Voron T,Pernot S.Control of the immune response by pro-angiogenic factors.Front Oncol2014;4:70 PMCID:PMC3980099

[22] Lee MS,Hsu CH.GO30140 investigatorsAtezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.Lancet Oncol2020;21:808-20

[23] Sonbol MB,Naqvi SAA.Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.JAMA Oncol2020;6:e204930 PMCID:PMC7582230

[24] Casak SJ,Fashoyin-Aje L.FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma.Clin Cancer Res2020;27:1836-41

[25] Giannini EG,Borzio M.Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest GroupOverview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.ca cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice.Cancers (Basel)2019;11:1689 PMCID:PMC6896125

[26] Tovoli F,Trevisani F.Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: where are we now?.Vaccines (Basel)2020;8:578 PMCID:PMC7711845

[27] Alsina A,Vogel A.Effects of subsequent systemic anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.Liver Cancer2020;9:93-104 PMCID:PMC7024884

[28] Zhu AX,Edeline J.KEYNOTE-224 investigatorsPembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Lancet Oncol2018;19:940-52

[29] El-Khoueiry AB,Yau T.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017;389:2492-502 PMCID:PMC7539326

[30] Marrero JA,Venook AP.Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.J Hepatol2016;65:1140-7

[31] Labeur TA,Takkenberg B,Mathôt R.Sorafenib for patients with hepatocellular carcinoma and Child-Pugh B liver cirrhosis: lessons learned from a terminated study.Oncologist2020;25:e1274-9 PMCID:PMC7485346

[32] McNamara MG,Nuttall C.Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.Eur J Cancer2018;105:1-9

[33] Chen SC,Chen MH.Lenvatinib for the treatment of HCC: A single institute experience.J Clin Oncol2019;37:e15611

[34] Zhu AX,Malfertheiner P.Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma analysis of REACH trial results by child-pugh score.JAMA Oncol2017;3:235-43

[35] El-Khoueiry A,Cheng A.Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo.Abstr ESMO2020;31:S220

[36] Kudo M,Santoro A.Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.J Clin Oncol2019;37:327

[37] Rimassa L,Czauderna C,Galle P.Systemic treatment of HCC in special populations.J Hepatol2020;74:931-43

[38] Iavarone M,Czauderna C.Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.Am J Transplant2019;19:3176-84

[39] Sposito C,Germini A.Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.J Hepatol2013;59:59-66

[40] Pinter M,Peck-Radosavljevic M.Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.Gut2021;70:204-14 PMCID:PMC7788203